Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ERN1 | O75460 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471918 | 0.89 | EGFR (0.45) | ALDH1A1HPGDLMNAMAPK1L3MBTL1 | |
| SCHEMBL2471066 | 0.85 | L3MBTL1 (0.53) | ALDH1A1HPGDLMNAMAPK1L3MBTL1 | |
| SCHEMBL2471798 | 0.85 | LMNA (0.47) | ALDH1A1LMNAMAPK1L3MBTL1ERN1 | |
| SCHEMBL2475619 | 0.84 | ESR1 (0.41) | ALDH1A1LMNAMAPK1L3MBTL1ERN1 | |
| SCHEMBL2474677 | 0.83 | IKBKB (0.42) | SLC6A3SLC6A4ALDH1A1LMNAMAPK1 | |
| SCHEMBL2468601 | 0.82 | GSK3A (0.46) | LMNAMAPK1L3MBTL1ERN1 | |
| SCHEMBL2470728 | 0.82 | TP53 (0.41) | HPGDLMNAMAPK1L3MBTL1ERN1 | |
| SCHEMBL2472069 | 0.81 | L3MBTL1 (0.51) | ALDH1A1HPGDLMNAMAPK1L3MBTL1 | |
| SCHEMBL2472895 | 0.81 | ERN1 (0.38) | LMNAMAPK1L3MBTL1ERN1TDP1 | |
| SCHEMBL2472614 | 0.81 | CYP19A1 (0.50) | ALDH1A1ERN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2370422-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010056767-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | SLC6A3 3588/4885SLC6A2 3707/4885SLC6A4 4111/4885 |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | SLC6A3 3588/4885SLC6A2 3707/4885SLC6A4 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.